A.Vogel MenoSupport Complex
Natural health product licensed in Canada
- Other names
- A. Vogel Menopause Support
- Licence holder
- Bioforce Canada Inc.
- NPN or DIN-HM
- 80080807
- Status
- Inactive licence
- Licence date
- 23 October 2017
- Revision date
- 3 April 2018
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Dose déclarée au-delà d'une limite
Magnésium: up to 810 mg a day according to the dosing instructions published by Health Canada (2 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 300 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- À vérifier
Magnésium: up to 810 mg a day according to the dosing instructions published by Health Canada, above the limite de sécurité from EFSAEuropean Food Safety Authority. for adults (250 mg a day). Pour ce nutriment, le repère de l'EFSA ne porte que sur les apports ajoutés (compléments, aliments enrichis), pas sur ce qu'apporte l'alimentation courante.
limite supérieure de sécurité (UL). EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Conditions légales
Glycine max. (L.) Merr.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Magnésium Source : Magnesium citrate, tribasic | 56.7 milligramme | 113,400 µg |
| Magnésium Source : Magnesium citrate, tribasic | 405 milligramme | 810,000 µg |
| Glycine max Source : Glycine max- Haricot Extract : Matériel brut sec Extraction ratio : 400:1 Dry plant equivalent : 16,800 mg Potency : 60 % Isoflavones | 42 milligramme | Not calculated |
| Glycine max Source : Glycine max- Haricot Potency : 15 mg of aglycone isoflavone equivalent | Not specified | Not calculated |
Non-medicinal ingredients
Concentré de jus de betterave, Stéarate de magnésium, Huile de fruit de Litsea Cubeba, Huile essentielle de pelure de citron, Huile essentielle de verveine des Indes orientale, Cellulose microcristalline
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes de sexe féminin | Not specified | 1 Comprimé | 2 Tous les jours |
Uses authorised in Canada
Soy extract may reduce the frequency and severity of menopausal symptoms. Magnesium is a factor in the maintenance of good health. Magnesium helps in the development and maintenance of bones. Magnesium helps to maintain the body's ability to metabolize nutrients. Magnesium helps in energy metabolism and tissue formation.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use if you currently have or previously had breast cancer and/or breast tumours or if you have a predisposition to breast cancer, as indicated by an abnormal mammogram and/or biopsy, or a family member with breast cancer.
- Précautions et mises en garde
Ensure you are up-to-date on mammograms and gynaecological evaluations prior to use. Consult a health care practitioner if symptoms worsen. Consult a health care practitioner prior to use if you have a liver disorder or develop liver-related symptoms (e.g. abdominal pain, jaundice, dark urine); if you have a history of hormonal or gynaecological disease, including ovarian cancer, endometriosis, and/or uterine fibroids; or if you are taking blood thinners or hormone replacement therapy (HRT), including thyroid replacement therapy. Discontinue use and consult a health care practitioner if you experience breast pain, discomfort and/or tenderness, or if you experience a recurrence of menstruation and/or uterine spotting.
Source
Official Health Canada record, licence 80080807
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2018. Photograph the packaging to check whether it has changed. Photograph the packaging